Laura Pasetto
Overview
Explore the profile of Laura Pasetto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kebede V, Di Sapia R, Tonesi N, Rizzi M, Balosso S, Spallaci D, et al.
Epilepsia
. 2025 Feb;
PMID: 39982429
Objective: Physical exercise may improve neurological deficits and neuronal damage after acute brain injuries and decrease established seizures. We investigated whether voluntary running wheel (RW) activity affects epileptogenesis in a...
2.
Hausmann F, Caldi Gomes L, Hanzelmann S, Khatri R, Oller S, Gebelin M, et al.
Gigascience
. 2024 Dec;
13.
PMID: 39693632
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, which still lacks effective disease-modifying therapies. Similar to other neurodegenerative disorders, such as Alzheimer and Parkinson disease, ALS pathology...
3.
Gianferrari G, Cuoghi Costantini R, Crippa V, Carra S, Bonetto V, Pansarasa O, et al.
Brain Commun
. 2024 Sep;
6(5):fcae304.
PMID: 39291166
In preclinical studies, the anti-inflammatory drug colchicine, which has never been tested in amyotrophic lateral sclerosis, enhanced the expression of autophagy factors and inhibited accumulation of transactive response DNA-binding protein...
4.
Pupillo E, Bianchi E, Bonetto V, Pasetto L, Bendotti C, Paganoni S, et al.
Brain Behav Immun
. 2024 Aug;
122:456-462.
PMID: 39182589
Background: Positive effects of RNS60 on respiratory and bulbar function were observed in a phase 2 randomized, placebo-controlled trial in people with amyotrophic lateral sclerosis (ALS). Objective: to investigate the...
5.
Tortarolo M, Re Cecconi A, Camporeale L, Margotta C, Nardo G, Pasetto L, et al.
Neurobiol Dis
. 2024 Jun;
199:106576.
PMID: 38914173
Variability in disease onset and progression is a hallmark of amyotrophic lateral sclerosis (ALS), both in sporadic and genetic forms. Recently, we found that SOD1-G93A transgenic mice expressing the same...
6.
Caldi Gomes L, Hanzelmann S, Hausmann F, Khatri R, Oller S, Parvaz M, et al.
Nat Commun
. 2024 Jun;
15(1):4893.
PMID: 38849340
Amyotrophic lateral sclerosis (ALS) is a debilitating motor neuron disease and lacks effective disease-modifying treatments. This study utilizes a comprehensive multiomic approach to investigate the early and sex-specific molecular mechanisms...
7.
Mercurio D, Pischiutta F, Seminara S, Tribuzio F, Lisi I, Pasetto L, et al.
J Neuroinflammation
. 2024 May;
21(1):141.
PMID: 38807149
The lectin pathway (LP) of complement mediates inflammatory processes linked to tissue damage and loss of function following traumatic brain injury (TBI). LP activation triggers a cascade of proteolytic events...
8.
Kebede V, Ravizza T, Balosso S, Di Sapia R, Canali L, Soldi S, et al.
Brain Behav Immun
. 2024 Apr;
119:363-380.
PMID: 38608741
The gut microbiota is altered in epilepsy and is emerging as a potential target for new therapies. We studied the effects of rifaximin, a gastrointestinal tract-specific antibiotic, on seizures and...
9.
Golia M, Frigerio R, Pucci S, Sironi F, Margotta C, Pasetto L, et al.
Exp Neurol
. 2024 Feb;
374:114716.
PMID: 38331161
SOD1 gene is associated with progressive motor neuron degeneration in the familiar forms of amyotrophic lateral sclerosis. Although studies on mutant human SOD1 transgenic rodent models have provided important insights...
10.
Bernardotto S, Frasson I, Faravelli S, Morelli A, Schiavon E, Yuri Moscatiello G, et al.
Biomaterials
. 2023 Nov;
303:122394.
PMID: 38007919
Nanodecoy systems based on analogues of viral cellular receptors assembled onto fluid lipid-based membranes of nano/extravescicles are potential new tools to complement classic therapeutic or preventive antiviral approaches. The need...